DOES THE DRUG piracetam improve the cognition of children with Down syndrome?1 In contrast with exuberant testimonials appearing on television and the Internet, Lobaugh et al2 found no substantial benefit in their randomized controlled study. Despite the trial's relatively small cohort size, its rigorous double-blinded crossover design should earn our respect, while their findings (especially of undesirable behavioral effects) should temper our enthusiasm for piracetam markedly.
Feudtner C. Child Advocacy and Robust Community-Centered Research. Arch Pediatr Adolesc Med. 2001;155(4):438–439. doi:10.1001/archpedi.155.4.438
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.